Trial
NCT04046848
Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Octapharma
Collaborators
—
Condition
Severe Hemophilia A
Intervention
OCTA101
Why stopped
Study was terminated due to SADRs
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-13